“We usually see a lot of delay in terms of coming for or seeking care”: an expert consultation on COVID testing and care pathways in low- and middle-income countries

Author:

Bonnet Gabrielle1,Bimba John2,Chavula Chancy3,Chifamba Harunavamwe N.4,Divala Titus5,Lescano Andres G.6,Majam Mohammed7,Mbo Danjuma8,Suwantika Auliya A.9,Tovar Marco A.10,Yadav Pragya11,Corbett Elisabeth L.1,Vassall Anna1,Jit Mark1

Affiliation:

1. London School of Hygiene & Tropical Medicine

2. Bingham University

3. Clinton Health Access Initiative

4. Harare Central Hospital

5. Kamuzu University of Health Sciences

6. Cayetano Heredia University

7. University of the Witwatersrand

8. Maitama hospital

9. Padjadjaran University

10. Socios En Salud Sucursal Perú

11. National Institute of Virology

Abstract

Abstract Background: Rapid diagnostic testing may support improved treatment of COVID patients. Understanding COVID testing and care pathways is important for assessing the impact and cost-effectiveness of testing in the real world, yet there is limited information on these pathways in low-and-middle income countries (LMICs). We therefore undertook an expert consultation to better understand testing policies and practices, clinical screening, the profile of patients seeking testing or care, linkage to care after testing, treatment, lessons learnt and expected changes in 2023 in LMICs. Methods: We organized a qualitative consultation with ten experts from seven LMICs identified through purposive sampling. We conducted structured interviews during six regional consultations, and undertook a thematic analysis of the responses to our questions. Results: Participants reported that, after initial efforts to scale-up testing (which often encountered delays), the policy priority given to COVID testing has declined. Comorbidities putting patients at heightened risk (e.g., diabetes) mainly relied on self-identification. The decision to test following clinical screening was highly context- and location-specific, often dictated by local epidemiology and test availability. When rapid diagnostic tests were available, public sector healthcare providers tended to rely on them for diagnosis, while private sector providers predominantly used polymerase chain reaction (PCR) tests. Positive test results were generally taken at ‘face value’ by clinicians, although negative tests with a high index of suspicion may be confirmed with PCR. However, even with a positive result, patients were not always linked to care in a timely manner because of reluctance to receiving care or delays in returning to care centres upon clinical deterioration. Countries often lacked multiple components of the range of therapeutics advised in WHO guidelines: notably so for oral antivirals designed for high-risk mild patients. Severely ill patients mostly received corticosteroids and, in higher-resourced settings, tocilizumab. Conclusions: Testing does not always prompt enhanced care, due to reluctance on the part of patients and limited therapeutic availability within clinical settings. Any analysis of the impact or cost-effectiveness of testing policies post pandemic needs to either consider investment in optimal treatment pathways or constrain estimates of benefits based on actual practice.

Publisher

Research Square Platform LLC

Reference17 articles.

1. Statement on the fifteenth meeting of the IHR. (2005) Emergency Committee on the COVID-19 pandemic [Internet]. Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.

2. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection: interim guidance. 2021.

3. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing - Interim guidance [Internet]. Geneva: World Health Organization. ; 2022. Report No.: WHO/2019-nCoV/Ag-RDTs/Self_testing/2022.1. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Ag-RDTs-Self_testing-2022.1.

4. Africa Centres for Disease Control and Prevention (Africa CDC), Union A. Interim Guidance on the Use of Rapid Antigen tests for COVID-19 Response [Internet]. 2020 Dec. Available from: https://africacdc.org/download/interim-guidance-on-the-use-of-rapid-antigen-tests-for-covid-19-response/.

5. Indian Council of Medical Research. Advisory on Use of Rapid Antigen Detection Test for COVID-19 [Internet]. 2020 Jun. Available from: https://www.icmr.gov.in/pdf/covid/strategy/Advisory_for_rapid_antigen_test14062020.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3